Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Geneā€¦


Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients

More here:
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene...

Related Posts